Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: kisspeptin-54 human IVF trials
Also known as: KP-54, Metastin
Kisspeptin-54 is the parent (full-length, 54-amino-acid) isoform of kisspeptin, activating GPR54 (KISS1R) receptors on GnRH neurons to stimulate gonadotropin release. A published study found subcutaneous infusion of kisspeptin-54 stimulated gonadotropin release in women, with the LH response positively correlating with basal estradiol levels - supporting kisspeptin administration (via subcutaneous infusion) as a potential future therapeutic route for infertility treatment. This is directly comparable to, and complements, the kisspeptin-10 (KP-10) human trial data already documented in this catalog (see that record for the sexually dimorphic response pattern and direct kisspeptin-10-vs-54 comparison data).
Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.
Data source: Phase 2 and proof-of-concept human IVF studies
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.
3.2-12.8 nmol/kg as a single oocyte-maturation trigger
Context: PMID 26192876
Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.
Route safety: Non-human or laboratory exposure. It cannot be converted into a human dose.
1.6-12.8 nmol/kg as a single trigger
Context: PMID 25036713
Formulation: Route-specific sterile formulation and professional handling requirements apply; concentration cannot be inferred from an oral or topical product.
Route safety: Research-study protocol only; it is not an approved or individualized instruction and should not be extrapolated to another route.
Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.
Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.
The previous row selected 9.6 nmol/kg as universally optimal and misstated a 77% clinical-pregnancy rate. The Phase 2 study tested 3.2-12.8 nmol/kg; pregnancy percentages were per transfer and subgroup-specific.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention Kisspeptin-54 or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.